Nicox and Immco to develop Sjögren's syndrome diagnostic device

Nicox has joined forces with Immco Diagnostics to offer tests for the early detection of Sjögren's syndrome.

The collaboration aims to give eye care practitioners and patients increased access to the test that offers potentially more efficient management of the chronic disease.

Undiagnosed Sjögren's syndrome could be discovered in as many as 1 in 10 dry eye patients and could lead to other disorders of the exocrine glands and an increased risk of lymphoma.

The new test, developed by researchers at the University at Buffalo, New York, USA, combines novel and traditional markers that support an accurate and early diagnosis with high sensitivity and specificity.

Nicox Inc Executive Vice President and General Manager, Mr Jerry St Peter, commented, “Immco is a well-established and innovative organization with a reputation for cutting edge science and high quality products. The addition of this new test into our portfolio synergizes well with our existing point-of-care offering, and will contribute to the momentum we are building in the marketplace with AdenoPlus.”